DermaGene and VitmiRS: a comprehensive systems analysis of genetic dermatological disorders

Rahman, Razia; Sharma, Isha; Gahlot, Lokesh Kumar; Hasija, Yasha

doi:10.1186/s41702-018-0028-5

Cited by 1 publication

(1 citation statement)

References 117 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polypharmacology-based integrated systems biology approaches along with computational modeling, pharmacological, and clinical studies are productive for identification of novel molecular determinants essential in drug discovery and development. It also aids in unraveling the understanding of the significant impact of a new drug on complex human diseases (Rahman et al 2018). A drug showing connections with multiple nodes (targets) in a network implies its high efficacious potential to control or inhibit the function of the particular target that is detrimental for regulatory pathways (Boran and Iyengar 2010).…”

Section: Scope Of Network-interaction Studies and Polypharmacologicalmentioning

confidence: 99%

Exploring vitiligo susceptibility and management: a brief review

Rahman

Hasija

2018

biomed dermatol

Self Cite

View full text Add to dashboard Cite

Background: Vitiligo is a common dermatological disorder of chronic depigmentation which is phenotypically characterized by white macules on the skin caused as a result of the systematic destruction of functional melanocytes. This review provides an overview of vitiligo, its etiopathogenesis and disease management, and also discusses the scope of network-interaction studies and polypharmacological studies in understanding vitiligo disease module. Methods: A narrative review of the relevant published literatures known to the authors that comprehensively discussed about vitiligo and its implications was conducted. Results: Emerging evidence underlines the existing connection between deregulated miRNA function and vitiligo pathogenesis. It has also been linked with autoimmunity for the cause of melanocyte death in susceptible individuals. Alteration of genetic factors involved in immune responses and melanogenesis along with environmental factors are central to disease manifestation. Screening methods as such are not available for vitiligo, and the diagnosis is based on the assessment of the absence of melanocytes from the lesions in the affected area. With the occurrence of vitiligo at any age, most people typically develop it at a young age. Depending on the disease course and duration, clinical management primarily involves disease stabilization either by repigmentation or depigmentation of the skin. Conclusions: Several questions remain unsolved which indeed makes vitiligo an excellent model for studying autoimmune and degenerative processes. An understanding of the underlying degenerative mechanisms and unraveling the biological mediators of melanocyte loss will open up avenues for testing novel therapeutic approaches in vitiligo management. Such studies can revolutionize our apprehension of the molecular interconnections that underpin vitiligo pathogenesis.

show abstract

Section: Scope Of Network-interaction Studies and Polypharmacologicalmentioning

confidence: 99%